Dr. Nancy Reid
Background: Advancements in medicine development have made available novel therapies that are improving the speed of therapy as well as overall clearance of plaque psoriasis. Objective: To compare biologic therapies based on existing data to determine net efficacy results related to PASI clearance scores for patients aiding in the providers’ selection of therapy for patients. Methods: A systemic literature review of most recent data over past five years on Psoriasis Area and Severity Index (PASI) responses for biologics. Research will focus on cumulative clinical benefit, measure by the area under the curve for PASI >75% (PASI 75), >90% improvement (PASI 90), and 100% improvement (PASI 100) as is common within plaque psoriasis studies (including phase III trials) using meta-analysis in studies accessed. Results: Overall, all medications within the biologic family of medications demonstrate efficacy for the clearance or partial clearance of plaque psoriasis. Statistically, anti-interleukin- 17 biologics are shown to demonstrate consistent greater cumulative clinical benefits on PASI 75, PASI 90, and PASI 100 over the time period in which studies are typically conducted (12-16 weeks). Conclusion: Review of data from resources obtained demonstrate that ixekizumab (Talz™) and brodalumab (Siliq™) may be more efficacious regarding PASI clearance scores to a measure of significance.
"Biologic Rationale for Treatment of Plaque Psoriasis,"
Lynchburg Journal of Medical Science: Vol. 3
, Article 99.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol3/iss3/99
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.